Wei Zheng

Dr. Wei Zheng

Department of Psychiatry, the Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
GWGang Wang
Gang Wang
Wei ZhengWei Zheng
Wei Zheng
XLXian-Bin Li
Xian-Bin Li
SWShi-Bin Wang
Shi-Bin Wang
DCDong-Bin Cai
Dong-Bin Cai
CCChristoph U. Correll
Christoph U. Correll

1 January 2017 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
YXYing-Qiang Xiang
Ying-Qiang Xiang
Wei ZhengWei Zheng
Wei Zheng
SWShi-Bin Wang
Shi-Bin Wang
XYXin-Hu Yang
Xin-Hu Yang
DCDong-Bin Cai
Dong-Bin Cai
YXYu-Tao Xiang
Yu-Tao Xiang

1 May 2020 in Journal of Affective Disorders
Verified
Journal Article
Closed access
Wei ZhengWei Zheng
Wei Zheng

19 September 2016 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
YWYuan‐Yuan Wang
Yuan‐Yuan Wang
Wei ZhengWei Zheng
Wei Zheng
CNChee H. Ng
Chee H. Ng
GUGabor S. Ungvari
Gabor S. Ungvari
WWWei Wei
Wei Wei
YXYu-Tao Xiang
Yu-Tao Xiang

27 September 2018 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
YZYanling Zhou
Yanling Zhou
Wei ZhengWei Zheng
Wei Zheng
WLWeijian Liu
Weijian Liu
CWChengyu Wang
Chengyu Wang
YZYanni Zhan
Yanni Zhan
YNYuping Ning
Yuping Ning
Background: Ketamine has proven to have rapid, robust antidepressant effects on treatment-resistant depression. However, whether repeated ketamine infusions would cause short-and long-term neurocognitive impairments was not clear. Our aims were to investigate the neurocognitive effects of six ketamine infusions and to examine the association between these infusions and the antidepressant response in patients with unipolar and bipolar depression. Methods: Six intravenous infusions of ketamine (0.5 mg/kg) over a 12-day period were administered to 84 patients with unipolar and bipolar depression. Severity of depressive symptoms and four domains of neurocognition, including speed of processing, working memory, visual learning and verbal learning, were assessed at baseline, one day following the last infusion and again two weeks post-infusion. Results: Significant improvements were found on speed of processing ( F=9.344, p<0.001) and verbal learning ( F=5.647, p=0.004) in a linear mixed model. The Sobel test showed significant indirect effects between time and improvement in speed of processing (Sobel test=3.573, p<0.001) as well as improvement in verbal learning (Sobel test=6.649, p<0.001), which were both significantly mediated by change in depressive symptoms. Logistic regression analysis showed ketamine responders had better visual learning at baseline than non-responders (B=0.118, p<0.001). Conclusions: Our findings suggest that neurocognitive function would not deteriorate after six ketamine infusions, while verbal learning and speed of processing improved over 13 days and 26 days of observation, respectively. However, this change was mainly accounted for by improvements in severity of depressive symptoms over time. Greater baseline visual learning predicted an antidepressant response over six ketamine infusions.

1 September 2016 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
Wei ZhengWei Zheng
Wei Zheng
YXYu-Tao Xiang
Yu-Tao Xiang
XLX.‐B. Li
X.‐B. Li
GUG. S. Ungvari
G. S. Ungvari
HCH. F. K. Chiu
H. F. K. Chiu
CCC. U. Correll
C. U. Correll